NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis $91.06 +0.46 (+0.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$90.29▼$92.7450-Day Range$82.78▼$95.3252-Week Range$70.74▼$97.97Volume284,816 shsAverage Volume512,291 shsMarket Capitalization$4.64 billionP/E Ratio39.76Dividend YieldN/APrice Target$109.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Haemonetics alerts: Email Address Haemonetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside20.3% Upside$109.50 Price TargetShort InterestBearish9.27% of Float Sold ShortDividend StrengthN/ASustainability-0.54Upright™ Environmental ScoreNews Sentiment0.69Based on 7 Articles This WeekInsider TradingSelling Shares$2.64 M Sold Last QuarterProj. Earnings Growth12.04%From $4.57 to $5.12 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.98 out of 5 starsMedical Sector228th out of 936 stocksSurgical & Medical Instruments Industry30th out of 101 stocks 2.4 Analyst's Opinion Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHaemonetics has only been the subject of 3 research reports in the past 90 days.Read more about Haemonetics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.27% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Haemonetics has recently increased by 10.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHaemonetics has received a 64.94% net impact score from Upright. Haemonetics seems to create the most significant positive value in categories "Taxes", "Physical diseases", and "Relationships". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Computerized clinical decision support software", "Hemofilters", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Haemonetics is -0.54. Previous Next 2.0 News and Social Media Coverage News SentimentHaemonetics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Haemonetics this week, compared to 6 articles on an average week.MarketBeat FollowsOnly 3 people have added Haemonetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,638,056.00 in company stock.Percentage Held by InsidersOnly 1.80% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Haemonetics are expected to grow by 12.04% in the coming year, from $4.57 to $5.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 39.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 39.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 157.66.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 1.67. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 4.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Haemonetics Stock (NYSE:HAE)Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Read More HAE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HAE Stock News HeadlinesJuly 16, 2024 | insidertrades.comInsider Selling: Haemonetics Co. (NYSE:HAE) EVP Sells 2,136 Shares of StockJuly 27 at 1:14 AM | americanbankingnews.comHaemonetics Co. (NYSE:HAE) Receives $109.50 Consensus Target Price from AnalystsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 9:55 PM | msn.comStudy: Iron infusions superior to blood transfusions for surgical patients with anemiaJuly 22, 2024 | uk.finance.yahoo.comT. Rowe Price US Smlr Cm Eq C Acc H GBP (0P0001LQSL.L)July 17, 2024 | americanbankingnews.comAnila Lingamneni Sells 2,136 Shares of Haemonetics Co. (NYSE:HAE) StockJuly 8, 2024 | prnewswire.comHaemonetics Sets Date for Publishing First Quarter Fiscal Year 2025 Results: August 8, 2024June 21, 2024 | seekingalpha.comHaemonetics Undervalued As It Passes Into A Period Of Softer Reported GrowthJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 18, 2024 | prnewswire.comHaemonetics Launches Limited Market Release for New VASCADE MVP XL Vascular Closure DeviceMay 23, 2024 | markets.businessinsider.comHaemonetics Prices $600 Mln, 2.5% Convertible Sr. NotesMay 23, 2024 | prnewswire.comHaemonetics Prices Upsized Private Placement of $600 Million Convertible Senior NotesMay 22, 2024 | finance.yahoo.comInsider Sale: EVP Josep Llorens Sells Shares of Haemonetics Corp (HAE)May 21, 2024 | prnewswire.comHaemonetics Announces Proposed Convertible Senior Notes OfferingMay 17, 2024 | markets.businessinsider.comHaemonetics Stock Up 10.9% YTD: Will the Rally Continue?May 14, 2024 | markets.businessinsider.comHaemonetics Positioned for Strong Growth: Buy Rating Justified Amidst Operational and Financial OptimismMay 10, 2024 | finanznachrichten.deHaemonetics Corporation: Haemonetics 4th Quarter and Fiscal Year 2024 Earnings Release Available on Investor Relations WebsiteMay 10, 2024 | markets.businessinsider.com4 Analysts Assess Haemonetics: What You Need To KnowSee More Headlines Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNYSE:HAE CUSIP40502410 CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,657Year Founded1971Price Target and Rating Average Stock Price Target$109.50 High Stock Price Target$125.00 Low Stock Price Target$94.00 Potential Upside/Downside+19.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.29 Trailing P/E Ratio39.93 Forward P/E Ratio20.01 P/E Growth1.67Net Income$117.56 million Net Margins8.98% Pretax Margin11.60% Return on Equity22.25% Return on Assets9.73% Debt Debt-to-Equity Ratio0.83 Current Ratio2.56 Quick Ratio1.50 Sales & Book Value Annual Sales$1.31 billion Price / Sales3.56 Cash Flow$6.06 per share Price / Cash Flow15.10 Book Value$18.90 per share Price / Book4.84Miscellaneous Outstanding Shares50,950,000Free Float50,036,000Market Cap$4.66 billion OptionableOptionable Beta0.29 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Christopher A. Simon (Age 60)CEO, President & Director Comp: $3.26MMs. Anila Lingamneni (Age 56)Executive VP & CTO Comp: $1.09MMs. Michelle L. Basil (Age 52)Executive VP, General Counsel & Secretary Comp: $1.26MMr. Josep Lluis Llorens (Age 62)Executive Vice President of Global Manufacturing & Supply Chain Comp: $1.11MMs. Olga GuyetteSenior Director of Investor RelationsMr. Rajeev VarmaSenior Vice President of Strategy & Corporate DevelopmentMs. Laurie A. Miller (Age 51)Senior VP & Chief Human Resources Officer Dr. Jan Hartmann M.D.Senior VP & Chief Medical OfficerMr. Stewart W. Strong (Age 57)President of Global Hospital Comp: $918.03kMs. Kerri DiPietroSenior Vice President of Global Quality AssuranceMore ExecutivesKey CompetitorsAlign TechnologyNASDAQ:ALGNDENTSPLY SIRONANASDAQ:XRAYMerit Medical SystemsNASDAQ:MMSINeogenNASDAQ:NEOGICU MedicalNASDAQ:ICUIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 1,096 shares on 7/26/2024Ownership: 0.954%Allspring Global Investments Holdings LLCSold 50,826 shares on 7/26/2024Ownership: 0.887%State of Michigan Retirement SystemSold 200 shares on 7/26/2024Ownership: 0.024%Legato Capital Management LLCBought 614 shares on 7/26/2024Ownership: 0.016%Louisiana State Employees Retirement SystemSold 200 shares on 7/24/2024Ownership: 0.028%View All Insider TransactionsView All Institutional Transactions HAE Stock Analysis - Frequently Asked Questions How have HAE shares performed this year? Haemonetics' stock was trading at $85.51 on January 1st, 2024. Since then, HAE stock has increased by 6.5% and is now trading at $91.06. View the best growth stocks for 2024 here. How were Haemonetics' earnings last quarter? Haemonetics Co. (NYSE:HAE) posted its quarterly earnings results on Thursday, May, 9th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.02. The firm's revenue for the quarter was up 12.7% on a year-over-year basis. What is Christopher Simon's approval rating as Haemonetics' CEO? 48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are Haemonetics' major shareholders? Haemonetics' top institutional shareholders include Boston Trust Walden Corp (1.40%), Bank of New York Mellon Corp (0.95%), Allspring Global Investments Holdings LLC (0.89%) and Retirement Systems of Alabama (0.35%). Insiders that own company stock include Christopher Simon, Michelle L Basil, Anila Lingamneni, Josep Llorens, Stewart W Strong, Laurie A Miller and Dan Goldstein. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN) and This page (NYSE:HAE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
